^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Hodgkin Lymphoma
    Drug:bortezomib (Proteasome inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    09/28/2020
    Excerpt:
    Pediatric Hodgkin Lymphoma...Subsequent Therapy Options: Bortezomib+ifosfamide+vinorelbine.
    Secondary therapy:
    ifosfamide + vinorelbine tartrate